ARDX Share Price Performance
US$6.55
1.19 (22.20%)
34.5% undervalued intrinsic discount
US$10.00
Fair Value
Price US$6.55
AnalystLowTarget US$10.00
AnalystConsensusTarget US$13.50
AnalystHighTarget US$19.00
Fair ValueUS$10.00
Share Pricen/a
Ardelyx, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 122 Fair Values set on narratives written by author
ARDX Community Narratives
AN
Fair Value US$10 34.5% undervalued intrinsic discount
Pricing And Regulation Risks Will Undercut Revenue Yet Yield Recovery
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
Fair Value US$13.5 51.5% undervalued intrinsic discount
Global Healthcare And Aging Trends Will Unleash Market Opportunity
0users have liked this narrative
0users have commented on this narrative
63users have followed this narrative
AN
Fair Value US$19 65.5% undervalued intrinsic discount
Accelerating CKD And IBS-C Demand Will Transform Treatment Landscape
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Accelerating CKD And IBS-C Demand Will Transform Treatment Landscape
Key Takeaways Surging product sales, prescriber engagement, and market expansion point to potential revenue and margin growth exceeding current projections for both major drugs. Operational leverage, global partnerships, and a strengthened balance sheet offer increased margin expansion and recurring revenue opportunities, fueling future enterprise value.Read more
23
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$19
65.5% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
36.76% p.a.
Profit Margin
38.81%
Future PE
15.34x
Price in 2029
US$23.48
Pricing And Regulation Risks Will Undercut Revenue Yet Yield Recovery
Key Takeaways Heavy reliance on a few key products leaves Ardelyx exposed to reimbursement challenges, pricing pressures, and strong competition in core therapeutic areas. Expanding regulatory scrutiny, rising compliance and R&D costs, and restricted drug market access threaten net margins and delay sustainable profitability.Read more
58
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
US$10
34.5% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
26.04% p.a.
Profit Margin
19.53%
Future PE
20.38x
Price in 2029
US$12.47
Global Healthcare And Aging Trends Will Unleash Market Opportunity
Key Takeaways Expanding markets, better market access, and prescription growth are accelerating adoption of core therapies, supporting sustained revenue and margin improvement. International partnerships and new indications diversify revenue streams, mitigate risks, and enhance long-term earnings stability.Read more
423
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
63users have followed this narrative
AN
US$13.5
51.5% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
28.43% p.a.
Profit Margin
32.59%
Future PE
15.58x
Price in 2029
US$16.83
Trending Discussion
Recently Updated Narratives
AN
ARDX: Extended Patent Runway And 2029 Revenue Path Will Support Bullish Outlook
Fair Value: US$19 65.5% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ARDX: Multiyear Revenue Roadmap And CIC Expansion Will Drive Upside
Fair Value: US$10 34.5% undervalued intrinsic discount
5 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ARDX: Faster Path To 1b Revenue Is Expected To Unlock Upside
Fair Value: US$13.5 51.5% undervalued intrinsic discount
63 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Ardelyx, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.25
- 72.73%
- -15.12%
- 137.0%
About ARDX
- Founded
- 2007
- Employees
- 489
- CEO
- WebsiteView website
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
